U.S. Drug Utilization Management Market Summary

The U.S. drug utilization management market size was estimated at USD 37.25 billion in 2023 and is anticipated to grow at a compound annual growth rate (CAGR) of 7.30% from 2024 to 2030. This expected growth is attributed to the increasing implementation of automated utilization management services and the rising demand for improved prescription practices, especially for specialty drugs. These efforts aim to reduce overall healthcare expenditures while enhancing patient outcomes. As drug prices and healthcare costs continue to escalate, optimizing drug utilization through efficient management strategies is becoming critical to sustaining the healthcare system and improving value-based care.

Drug utilization management strategies include various tools such as Prior Authorizations (PAs), step therapy protocols, and quantity limits. These methods are specifically designed to ensure that medications are prescribed and used appropriately, thereby minimizing unnecessary drug consumption, medical errors, and overall treatment costs. These criteria are integral in promoting cost control and influencing clinical decision-making to ensure high-quality care. Greater collaboration between healthcare providers, payers, and pharmacists is being emphasized to improve the efficiency of these programs. The objective is to ensure that patients receive the most appropriate medications in a timely and cost-effective manner, without compromising the quality of treatment.

The future of drug utilization management is expected to be shaped by enhanced pharmacist involvement in the PA process, widespread adoption of Electronic Prior Authorization (ePA) tools, and the development of national best practices and standards for electronic health data exchange. These advancements are expected to streamline approval workflows, reduce administrative burdens, and improve access to necessary medications. As the healthcare ecosystem evolves, more robust and digitally enabled solutions are being deployed to address inefficiencies and facilitate seamless coordination among stakeholders involved in prescription drug management.

Key Market Trends & Insights

• Based on program type, the in-house segment emerged as the dominant category, accounting for the largest revenue share of 65.10% in 2023. The popularity of in-house programs can be attributed to the cost advantages, operational efficiencies, and increased control they offer to health plans and employers. These internal programs allow organizations to tailor utilization management strategies to their specific populations, thereby improving care delivery and reducing unnecessary expenditures.
• In terms of end-use, the pharmacy benefit managers (PBMs) segment led the market in 2023, with a significant share of 37.19%. Moreover, it is projected to witness the fastest growth rate throughout the forecast period. PBMs play a pivotal role in the pharmaceutical supply chain by negotiating discounted drug prices, securing manufacturer rebates, and managing formularies. Their growing influence and ability to reduce drug spending make them key stakeholders in the overall utilization management landscape.
• The health plan providers/payers segment is also expected to experience substantial growth during the forecast period. This growth will be supported by rising healthcare costs in the United States and a heightened focus among stakeholders on identifying and mitigating the root causes of elevated drug spending. As value-based healthcare continues to evolve, payers are leveraging utilization management programs to better align prescription practices with cost-effective and outcome-focused care delivery models.

Order a free sample PDF of the U.S. Drug Utilization Management Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 37.25 billion
• 2030 Projected Market Size: USD 60.68 billion
• CAGR (2024 - 2030): 7.30%

Key Companies & Market Share Insights

The market is highly competitive, with the presence of major players such as Optum, Inc.; Prime Therapeutics LLC.; and MedicusRx. Many notable health insurers have acquired or partnered with PBM companies, creating vertically integrated healthcare organizations. While the market is dominated by a few large players, there are emerging competitors, such as nonprofit partnerships, creating new PBMs to offer services for employers.

Key Players

Third Party Providers:

• Prime Therapeutics LLC
• MedicusRx
• EmblemHealth
• Optum, Inc.
• Point32Health, Inc.
• AssureCare LLC
• MindRx Group
• Agadia Systems, Inc
• Elevance Health (CarelonRx)
• ExlService Holdings, Inc.
• MRIoA
• S&C Technologies, Inc.

In-House Providers:

• Ultimate Health Plans
• Security Health Plan of Wisconsin, Inc.
• Blue Cross and Blue Shield Association
• Providence
• Simply Healthcare Plans, Inc
• Health Plan of San Mateo (HPSM)
• PerformRx
• Aetna, Inc. (CVS Health Corp.)

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

In conclusion, the U.S. drug utilization management market is poised for steady growth due to increasing demand for cost-effective drug therapies, rising healthcare spending, and the growing adoption of automation and ePA systems. With the in-house segment leading in program type and PBMs playing a crucial role in price negotiations and benefit optimization, stakeholders are prioritizing strategies that improve care quality while controlling costs. As digital transformation and regulatory support continue to shape the healthcare landscape, utilization management will be instrumental in optimizing therapy decisions and enhancing patient access to appropriate medications in a more efficient and timely manner.